fda warning on semaglutide Some people are overdosing semaglutide, warns | What you should know FDA Adds New Warning for

What to do If your weight loss has plateaued, it may not be about trying harder

The STEP 4 trial This step provides important insights into the effectiveness of semaglutide, a glucagon-like peptide 1 receptor agonist, for weight loss maintenance in individuals with overweight or obesity

Placebo-adjusted changes in time in range, weight and HbA1c were 6.2 (9.7) percentage points, 6.3 (5.7) kg and 0.7% (0.3) in those with detectable C-peptide levels compared to 4.4 (7.1) percentage points, 6.4 (3.4) kg and 0.4% (0.3) in those with undetectable levels (Supplementary Table 11)

Regular thyroid function tests (TSH and free T4) are recommended during treatment, particularly if significant weight loss occurs

Whilst not everyone experiences sickness, it is sufficiently common that healthcare professionals routinely counsel patients about this possibility before starting treatment

What matters most is consistency in your dosing schedule and using proper injection technique